447 | POLATUZUMAB‐CONTAINING REGIMENS AS BRIDGE TO CAR‐T: INSIGHTS FROM THE ITALIAN CAR T‐SIE STUDY
Giulia Gabrielli(Hospital of the University of Pennsylvania), P. L. Zinzani(Istituto di Ematologia di Bologna), Mirko Farina(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Maria Chiara Tisi(Ospedale San Bortolo), Benedetta Casadei(Azienda USL di Bologna), Giovanni Grillo(Azienda Socio Sanitaria Territoriale Lariana), Carlo Visco(University of Verona), Lisa Argnani(Istituto di Ematologia di Bologna), Lucia Brunello(University of Turin), P. Corradini(Fondazione IRCCS Istituto Nazionale dei Tumori), Daniele Mannina(Humanitas University), Annalisa Chiappella(Palmetto Hematology Oncology), Mattia Novo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), A. Di Rocco, Eugenio Galli(Agostino Gemelli University Polyclinic), Giuseppe Petruzzellis(Ospedale Santa Maria della Misericordia di Udine), Alessandra Crescimanno(La Maddalena), Francesca Bonifazi(University of Bologna), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Federica Cavallo(University of Turin), Massimo Martino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Ilaria Cutini(Azienda Ospedaliero-Universitaria Careggi)
Cited by 0
Related Papers
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction
|Cell|1992|1.3k
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523